Grifols, Selagine partner to develop immunoglobin dry eye treatment
Click Here to Manage Email Alerts
Grifols announced a global collaboration and licensing agreement with Selagine to develop immunoglobin eye drops for the treatment of dry eye disease, in a company press release.
The drops would be Grifols’ first-ever ocular surface indicated medicine, as well as its first product for dry eye disease.
“Grifols is very excited to combine our synergistic strengths with Selagine in a potentially game-changing treatment for an unmet medical need that can help millions of patients globally with dry eye disease,” Victor Grifols Deu, Grifols co-CEO, said in the release. “We are committed to maximizing our deep and ever-growing knowledge of immunoglobulins to treat the broadest range of therapeutic areas.”
In a pilot phase 1/2 clinical trial, Selagine treated study participants with eye drops based on Grifols Flebogamma DIF twice daily for 8 weeks and reported significant reduction in the signs and symptoms of dry eye disease, the release stated.
“Selagine and Grifols have an exceptional opportunity to change the paradigm of dry eye treatment through a novel approach that has the potential to significantly improve the quality of life of patients suffering from this condition,” Sandeep Jain, MD, founder and president of Selagine and BA Field Professor of Ophthalmology at the University of Illinois Chicago of Medicine, said in the release.
Read more about
Click Here to Manage Email Alerts